CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
EN
Home / Olema Pharmaceuticals, INC. (OLMA) / palazestrant
Forward catalyst · OLMA

palazestrant

Sponsor Olema Pharmaceuticals, INC. · listed as OLMA

READOUT Phase 3 Confidence: medium Source: clinicaltrials

palazestrant is a clinical-stage drug asset sponsored by Olema Pharmaceuticals, INC., listed as OLMA. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Oct 31, 2026 (day precision, medium confidence), tied to trial NCT06016738. The asset is in Phase 3 and currently active not recruiting, studied in Breast Cancer. It appears across 2 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-10-31
As disclosedOct 31, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06016738
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorOlema Pharmaceuticals, Inc.
Listed asOLMA
Condition(s)Breast Cancer; Advanced Breast Cancer; Metastatic Breast Cancer; ER Positive Breast Cancer; HER2 Negative Breast Carcinoma
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.

Get the full dataset — $499 →   More OLMA catalysts

Related catalysts and sponsor